Alterations in noradrenergic function during clorgyline treatment

David Pickar, C. Raymond Lake, Robert M. Cohen, David C. Jimerson, Dennis L. Murphy

Research output: Contribution to journalArticle

Abstract

The effect of four weeks treatment with the selective monoamine oxidase (MAO-A) Type A inhibitor, clorgyline, on noradrenergic function was assessed in depressed patients using steady-state intravenous tyramine pressor response tests and determinations of plasma norepinephrine (NE). During the pretreatment period: 1) resting levels of plasma NE were correlated (r = .82) with tyramine sensitivity as indicated by the dose (mg/min) of infused tyramine required to elevate and maintain systolic blood pressure 30 mmHg; 2) significant increases in plasma NE accompanied steady-state rise in blood pressure; and 3) the magnitude of tyramine stimulated NE increases were highly correlated (r = .91) with pretreatment plasma NE levels. Clorgyline administration for 3-4 weeks was accompanied by: 1) large increases in pressor sensitivity to intravenous tyramine; 2) significant decreases in resting levels of plasma NE; 3) alterations in the relationship between plasma NE and tyramine sensitivity; and 4) a trend towards a reduction in the tyramine-stimulated plasma NE release. A postulated clorgyline-induced down-regulation of presynaptic adrenergic activity is discussed with regard to the overall enhancement in tyramine pressor sensitivity produced by clorgyline.

Original languageEnglish (US)
Pages (from-to)379-386
Number of pages8
JournalCommunications In Psychopharmacology
Volume4
Issue number5
StatePublished - 1980
Externally publishedYes

Fingerprint

Clorgyline
Tyramine
Norepinephrine
Therapeutics
Blood Pressure
Monoamine Oxidase
Adrenergic Agents
Down-Regulation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pickar, D., Lake, C. R., Cohen, R. M., Jimerson, D. C., & Murphy, D. L. (1980). Alterations in noradrenergic function during clorgyline treatment. Communications In Psychopharmacology, 4(5), 379-386.

Alterations in noradrenergic function during clorgyline treatment. / Pickar, David; Lake, C. Raymond; Cohen, Robert M.; Jimerson, David C.; Murphy, Dennis L.

In: Communications In Psychopharmacology, Vol. 4, No. 5, 1980, p. 379-386.

Research output: Contribution to journalArticle

Pickar, D, Lake, CR, Cohen, RM, Jimerson, DC & Murphy, DL 1980, 'Alterations in noradrenergic function during clorgyline treatment', Communications In Psychopharmacology, vol. 4, no. 5, pp. 379-386.
Pickar D, Lake CR, Cohen RM, Jimerson DC, Murphy DL. Alterations in noradrenergic function during clorgyline treatment. Communications In Psychopharmacology. 1980;4(5):379-386.
Pickar, David ; Lake, C. Raymond ; Cohen, Robert M. ; Jimerson, David C. ; Murphy, Dennis L. / Alterations in noradrenergic function during clorgyline treatment. In: Communications In Psychopharmacology. 1980 ; Vol. 4, No. 5. pp. 379-386.
@article{f55c568351494c4da3ae3444b67d2b7f,
title = "Alterations in noradrenergic function during clorgyline treatment",
abstract = "The effect of four weeks treatment with the selective monoamine oxidase (MAO-A) Type A inhibitor, clorgyline, on noradrenergic function was assessed in depressed patients using steady-state intravenous tyramine pressor response tests and determinations of plasma norepinephrine (NE). During the pretreatment period: 1) resting levels of plasma NE were correlated (r = .82) with tyramine sensitivity as indicated by the dose (mg/min) of infused tyramine required to elevate and maintain systolic blood pressure 30 mmHg; 2) significant increases in plasma NE accompanied steady-state rise in blood pressure; and 3) the magnitude of tyramine stimulated NE increases were highly correlated (r = .91) with pretreatment plasma NE levels. Clorgyline administration for 3-4 weeks was accompanied by: 1) large increases in pressor sensitivity to intravenous tyramine; 2) significant decreases in resting levels of plasma NE; 3) alterations in the relationship between plasma NE and tyramine sensitivity; and 4) a trend towards a reduction in the tyramine-stimulated plasma NE release. A postulated clorgyline-induced down-regulation of presynaptic adrenergic activity is discussed with regard to the overall enhancement in tyramine pressor sensitivity produced by clorgyline.",
author = "David Pickar and Lake, {C. Raymond} and Cohen, {Robert M.} and Jimerson, {David C.} and Murphy, {Dennis L.}",
year = "1980",
language = "English (US)",
volume = "4",
pages = "379--386",
journal = "Communications In Psychopharmacology",
issn = "0145-5699",
number = "5",

}

TY - JOUR

T1 - Alterations in noradrenergic function during clorgyline treatment

AU - Pickar, David

AU - Lake, C. Raymond

AU - Cohen, Robert M.

AU - Jimerson, David C.

AU - Murphy, Dennis L.

PY - 1980

Y1 - 1980

N2 - The effect of four weeks treatment with the selective monoamine oxidase (MAO-A) Type A inhibitor, clorgyline, on noradrenergic function was assessed in depressed patients using steady-state intravenous tyramine pressor response tests and determinations of plasma norepinephrine (NE). During the pretreatment period: 1) resting levels of plasma NE were correlated (r = .82) with tyramine sensitivity as indicated by the dose (mg/min) of infused tyramine required to elevate and maintain systolic blood pressure 30 mmHg; 2) significant increases in plasma NE accompanied steady-state rise in blood pressure; and 3) the magnitude of tyramine stimulated NE increases were highly correlated (r = .91) with pretreatment plasma NE levels. Clorgyline administration for 3-4 weeks was accompanied by: 1) large increases in pressor sensitivity to intravenous tyramine; 2) significant decreases in resting levels of plasma NE; 3) alterations in the relationship between plasma NE and tyramine sensitivity; and 4) a trend towards a reduction in the tyramine-stimulated plasma NE release. A postulated clorgyline-induced down-regulation of presynaptic adrenergic activity is discussed with regard to the overall enhancement in tyramine pressor sensitivity produced by clorgyline.

AB - The effect of four weeks treatment with the selective monoamine oxidase (MAO-A) Type A inhibitor, clorgyline, on noradrenergic function was assessed in depressed patients using steady-state intravenous tyramine pressor response tests and determinations of plasma norepinephrine (NE). During the pretreatment period: 1) resting levels of plasma NE were correlated (r = .82) with tyramine sensitivity as indicated by the dose (mg/min) of infused tyramine required to elevate and maintain systolic blood pressure 30 mmHg; 2) significant increases in plasma NE accompanied steady-state rise in blood pressure; and 3) the magnitude of tyramine stimulated NE increases were highly correlated (r = .91) with pretreatment plasma NE levels. Clorgyline administration for 3-4 weeks was accompanied by: 1) large increases in pressor sensitivity to intravenous tyramine; 2) significant decreases in resting levels of plasma NE; 3) alterations in the relationship between plasma NE and tyramine sensitivity; and 4) a trend towards a reduction in the tyramine-stimulated plasma NE release. A postulated clorgyline-induced down-regulation of presynaptic adrenergic activity is discussed with regard to the overall enhancement in tyramine pressor sensitivity produced by clorgyline.

UR - http://www.scopus.com/inward/record.url?scp=0019301506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019301506&partnerID=8YFLogxK

M3 - Article

C2 - 7333093

AN - SCOPUS:0019301506

VL - 4

SP - 379

EP - 386

JO - Communications In Psychopharmacology

JF - Communications In Psychopharmacology

SN - 0145-5699

IS - 5

ER -